Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SELF
3126
Global Self Storage
SELF
$58.6M
| $249K | ﹤0.01% |
58,000
+20,295
| +54% | +$88.8K |
|
3127
USA Compression Partners
USAC
$3.84B
| $249K | ﹤0.01% |
+13,737
| New | +$234K |
|
3128
First Trust Financials AlphaDEX Fund
FXO
$1.15B
| $248K | ﹤0.01% |
7,400
-17,400
| -70% | -$566K |
|
3129
VolitionRx Ltd
VNRX
$7.6M
| $248K | ﹤0.01% |
2,615
-745
| -22% | -$77.2K |
|
3130
SIFCO Industries
SIF
$124M
| $247K | ﹤0.01% |
62,600
+4,500
| +8% | +$12.7K |
|
3131
Traws Pharma
TRAW
$8.12M
| $247K | ﹤0.01% |
1,720
+1,598
| +1,310% | +$299K |
|
|
NURO
3132
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
| $247K | ﹤0.01% |
7,172
-161
| -2% | -$4.66K |
|
|
FRTA
3133
DELISTED
Forterra, Inc
FRTA
| $247K | ﹤0.01% |
21,400
-6,900
| -24% | -$67.1K |
|
3134
Mind CTI
MNDO
$20.6M
| $246K | ﹤0.01% |
101,932
+19,115
| +23% | +$45.9K |
|
3135
MediciNova
MNOV
$65.5M
| $246K | ﹤0.01% |
+36,500
| New | +$274K |
|
|
RPT
3136
Rithm Property Trust
RPT
$99.9M
| $246K | ﹤0.01% |
2,864
-10,522
| -79% | -$934K |
|
|
APEN
3137
DELISTED
Apollo Endosurgery, Inc.
APEN
| $245K | ﹤0.01% |
85,900
+3,800
| +5% | +$11K |
|
|
STRR
3138
DELISTED
Star Equity Holdings
STRR
| $243K | ﹤0.01% |
18,704
| – | – |
|
|
BPMP
3139
DELISTED
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
| $243K | ﹤0.01% |
15,565
-6,094
| -28% | -$90.3K |
|
|
MRUS
3140
DELISTED
Merus
MRUS
| $242K | ﹤0.01% |
+17,200
| New | +$277K |
|
3141
Invesco Semiconductors ETF
PSI
$2.59B
| $242K | ﹤0.01% |
10,800
-1,200
| -10% | -$24.8K |
|
3142
Ring Energy
REI
$354M
| $242K | ﹤0.01% |
+91,600
| New | +$180K |
|
3143
Armata Pharmaceuticals
ARMP
$158M
| $241K | ﹤0.01% |
74,154
-1,500
| -2% | -$6.04K |
|
3144
El Pollo Loco
LOCO
$463M
| $241K | ﹤0.01% |
15,900
-21,400
| -57% | -$299K |
|
3145
Forestar Group
FOR
$1.49B
| $239K | ﹤0.01% |
11,480
-14,400
| -56% | -$281K |
|
|
TRVG
3146
trivago
TRVG
$367M
| $239K | ﹤0.01% |
+18,220
| New | +$277K |
|
|
BXG
3147
DELISTED
Bluegreen Vacations Corporation Common Stock
BXG
| $239K | ﹤0.01% |
+23,147
| New | +$227K |
|
3148
Loop Industries
LOOP
$32.2M
| $238K | ﹤0.01% |
24,000
+7,100
| +42% | +$76.4K |
|
|
MR
3149
DELISTED
Montage Resources Corporation Common Stock
MR
| $238K | ﹤0.01% |
+30,020
| New | +$157K |
|
3150
Arlo Technologies
ARLO
$1.5B
| $236K | ﹤0.01% |
+56,000
| New | +$193K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.